Tag: Immutep Limited
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Building resilience as manufacturing requirements become more complex
The industrial machinery and heavy equipment manufacturing sector is critical not only for its direct outputs, machines, and equipment that pave the way for construction, agriculture and manufacturing but also for its crucial role in economic development and innovation.
